questionsmedicales.fr
Régions géographiques
Océanie
Australasie
Australasie : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Australasie : Questions médicales les plus fréquentes",
"headline": "Australasie : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Australasie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-22",
"dateModified": "2025-04-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Australasie"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Océanie",
"url": "https://questionsmedicales.fr/mesh/D044349",
"about": {
"@type": "MedicalCondition",
"name": "Océanie",
"code": {
"@type": "MedicalCode",
"code": "D044349",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Australie",
"alternateName": "Australia",
"url": "https://questionsmedicales.fr/mesh/D001315",
"about": {
"@type": "MedicalCondition",
"name": "Australie",
"code": {
"@type": "MedicalCode",
"code": "D001315",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678.100.373"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Territoire de la capitale australienne",
"alternateName": "Australian Capital Territory",
"url": "https://questionsmedicales.fr/mesh/D020958",
"about": {
"@type": "MedicalCondition",
"name": "Territoire de la capitale australienne",
"code": {
"@type": "MedicalCode",
"code": "D020958",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678.100.373.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nouvelle-Galles du Sud",
"alternateName": "New South Wales",
"url": "https://questionsmedicales.fr/mesh/D009517",
"about": {
"@type": "MedicalCondition",
"name": "Nouvelle-Galles du Sud",
"code": {
"@type": "MedicalCode",
"code": "D009517",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678.100.373.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Territoire du Nord",
"alternateName": "Northern Territory",
"url": "https://questionsmedicales.fr/mesh/D015876",
"about": {
"@type": "MedicalCondition",
"name": "Territoire du Nord",
"code": {
"@type": "MedicalCode",
"code": "D015876",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678.100.373.875"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Queensland",
"alternateName": "Queensland",
"url": "https://questionsmedicales.fr/mesh/D011793",
"about": {
"@type": "MedicalCondition",
"name": "Queensland",
"code": {
"@type": "MedicalCode",
"code": "D011793",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678.100.373.937"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Australie-Méridionale",
"alternateName": "South Australia",
"url": "https://questionsmedicales.fr/mesh/D013021",
"about": {
"@type": "MedicalCondition",
"name": "Australie-Méridionale",
"code": {
"@type": "MedicalCode",
"code": "D013021",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678.100.373.968"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Tasmanie",
"alternateName": "Tasmania",
"url": "https://questionsmedicales.fr/mesh/D013648",
"about": {
"@type": "MedicalCondition",
"name": "Tasmanie",
"code": {
"@type": "MedicalCode",
"code": "D013648",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678.100.373.984"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Victoria",
"alternateName": "Victoria",
"url": "https://questionsmedicales.fr/mesh/D014739",
"about": {
"@type": "MedicalCondition",
"name": "Victoria",
"code": {
"@type": "MedicalCode",
"code": "D014739",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678.100.373.992"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Australie occidentale",
"alternateName": "Western Australia",
"url": "https://questionsmedicales.fr/mesh/D014904",
"about": {
"@type": "MedicalCondition",
"name": "Australie occidentale",
"code": {
"@type": "MedicalCode",
"code": "D014904",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678.100.373.996"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Nouvelle-Zélande",
"alternateName": "New Zealand",
"url": "https://questionsmedicales.fr/mesh/D009520",
"about": {
"@type": "MedicalCondition",
"name": "Nouvelle-Zélande",
"code": {
"@type": "MedicalCode",
"code": "D009520",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678.100.747"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Iles du Pacifique",
"alternateName": "Pacific Islands",
"url": "https://questionsmedicales.fr/mesh/D010139",
"about": {
"@type": "MedicalCondition",
"name": "Iles du Pacifique",
"code": {
"@type": "MedicalCode",
"code": "D010139",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "Z01.678.100.873"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Australasie",
"alternateName": "Australasia",
"code": {
"@type": "MedicalCode",
"code": "D044362",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Ainsley J Newson",
"url": "https://questionsmedicales.fr/author/Ainsley%20J%20Newson",
"affiliation": {
"@type": "Organization",
"name": "Faculty of Medicine and Health, Sydney School of Public Health, Sydney Health Ethics, The University of Sydney, Sydney, NSW, Australia."
}
},
{
"@type": "Person",
"name": "Thomas Beaney",
"url": "https://questionsmedicales.fr/author/Thomas%20Beaney",
"affiliation": {
"@type": "Organization",
"name": "Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London, UK."
}
},
{
"@type": "Person",
"name": "Xin Xia",
"url": "https://questionsmedicales.fr/author/Xin%20Xia",
"affiliation": {
"@type": "Organization",
"name": "Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London, UK."
}
},
{
"@type": "Person",
"name": "Neil R Poulter",
"url": "https://questionsmedicales.fr/author/Neil%20R%20Poulter",
"affiliation": {
"@type": "Organization",
"name": "Imperial Clinical Trials Unit, Imperial College London, Stadium House, 68 Wood Lane, London, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Diagnosis and Pathologic Reporting of Prostate Cancer in the Era of MRI-Targeted Prostate Biopsy.",
"datePublished": "2022-10-13",
"url": "https://questionsmedicales.fr/article/36344178",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.path.2022.07.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma: a case series.",
"datePublished": "2022-08-01",
"url": "https://questionsmedicales.fr/article/35926810",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.humpath.2022.07.018"
}
},
{
"@type": "ScholarlyArticle",
"name": "Determination of miRNA expression profile in patients with prostate cancer and benign prostate hyperplasia.",
"datePublished": "2022-06-16",
"url": "https://questionsmedicales.fr/article/36326314",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.55730/1300-0144.5374"
}
},
{
"@type": "ScholarlyArticle",
"name": "Causal relationship between prostatic diseases and prostate cancer: a mendelian randomization study.",
"datePublished": "2024-06-27",
"url": "https://questionsmedicales.fr/article/38937672",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12885-024-12551-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prostate MRI for the detection of clinically significant prostate cancer: Update and future directions.",
"datePublished": "2024-04-25",
"url": "https://questionsmedicales.fr/article/39032957",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/bs.acr.2024.04.002"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Régions géographiques",
"item": "https://questionsmedicales.fr/mesh/D005842"
},
{
"@type": "ListItem",
"position": 3,
"name": "Océanie",
"item": "https://questionsmedicales.fr/mesh/D044349"
},
{
"@type": "ListItem",
"position": 4,
"name": "Australasie",
"item": "https://questionsmedicales.fr/mesh/D044362"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Australasie - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Australasie",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Australasie",
"description": "Comment diagnostiquer une maladie tropicale en Australasie ?\nQuels tests sont utilisés pour le paludisme en Australasie ?\nComment identifier une infection par le virus Zika ?\nQuels sont les signes d'une infection à leptospirose ?\nComment diagnostiquer une maladie de Lyme en Australasie ?",
"url": "https://questionsmedicales.fr/mesh/D044362?mesh_terms=Prostatic+Neoplasms&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Australasie",
"description": "Quels sont les symptômes du chikungunya ?\nComment se manifeste la dengue ?\nQuels signes indiquent une infection par le virus de l'herpès ?\nQuels symptômes d'une intoxication alimentaire ?\nComment reconnaître une infection respiratoire ?",
"url": "https://questionsmedicales.fr/mesh/D044362?mesh_terms=Prostatic+Neoplasms&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Australasie",
"description": "Comment prévenir la dengue en Australasie ?\nQuelles mesures pour éviter le chikungunya ?\nComment se protéger contre le virus Zika ?\nQuelles sont les recommandations pour la leptospirose ?\nComment prévenir les infections respiratoires ?",
"url": "https://questionsmedicales.fr/mesh/D044362?mesh_terms=Prostatic+Neoplasms&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Australasie",
"description": "Quels traitements pour la dengue ?\nComment traiter une infection par le virus Zika ?\nQuels médicaments pour le chikungunya ?\nComment traiter une infection à leptospirose ?\nQuels sont les traitements pour la maladie de Lyme ?",
"url": "https://questionsmedicales.fr/mesh/D044362?mesh_terms=Prostatic+Neoplasms&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Australasie",
"description": "Quelles complications peuvent survenir avec la dengue ?\nQuels risques associés au chikungunya ?\nQuelles complications de l'infection par le virus Zika ?\nQuelles complications de la leptospirose ?\nQuels risques de la maladie de Lyme non traitée ?",
"url": "https://questionsmedicales.fr/mesh/D044362?mesh_terms=Prostatic+Neoplasms&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Australasie",
"description": "Quels sont les facteurs de risque pour la dengue ?\nQui est à risque pour le chikungunya ?\nQuels facteurs augmentent le risque de virus Zika ?\nQuels sont les risques associés à la leptospirose ?\nQui est à risque pour la maladie de Lyme ?",
"url": "https://questionsmedicales.fr/mesh/D044362?mesh_terms=Prostatic+Neoplasms&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une maladie tropicale en Australasie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur l'historique médical, les symptômes et des tests de laboratoire."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le paludisme en Australasie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de diagnostic incluent les frottis sanguins et les tests de dépistage rapide."
}
},
{
"@type": "Question",
"name": "Comment identifier une infection par le virus Zika ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'infection est confirmée par des tests sanguins spécifiques et l'historique de voyage."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une infection à leptospirose ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fièvre, douleurs musculaires et éruption cutanée, nécessitant des tests."
}
},
{
"@type": "Question",
"name": "Comment diagnostiquer une maladie de Lyme en Australasie ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'exposition aux tiques et des tests sérologiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes du chikungunya ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fièvre, douleurs articulaires et éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Comment se manifeste la dengue ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dengue se manifeste par une forte fièvre, des douleurs corporelles et des éruptions cutanées."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une infection par le virus de l'herpès ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des lésions cutanées, des démangeaisons et des douleurs localisées."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une intoxication alimentaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent nausées, vomissements, diarrhée et douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection respiratoire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent toux, fièvre, essoufflement et douleurs thoraciques."
}
},
{
"@type": "Question",
"name": "Comment prévenir la dengue en Australasie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éliminer les eaux stagnantes et utiliser des répulsifs contre les moustiques."
}
},
{
"@type": "Question",
"name": "Quelles mesures pour éviter le chikungunya ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des moustiquaires et des répulsifs, et éviter les zones infestées."
}
},
{
"@type": "Question",
"name": "Comment se protéger contre le virus Zika ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les piqûres de moustiques et utiliser des préservatifs lors de rapports sexuels."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour la leptospirose ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le contact avec des eaux potentiellement contaminées et porter des vêtements de protection."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections respiratoires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Se laver les mains régulièrement et éviter les contacts avec des personnes malades."
}
},
{
"@type": "Question",
"name": "Quels traitements pour la dengue ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est symptomatique, avec des analgésiques et une hydratation adéquate."
}
},
{
"@type": "Question",
"name": "Comment traiter une infection par le virus Zika ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique ; le repos et l'hydratation sont recommandés."
}
},
{
"@type": "Question",
"name": "Quels médicaments pour le chikungunya ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anti-inflammatoires et les analgésiques sont utilisés pour soulager les symptômes."
}
},
{
"@type": "Question",
"name": "Comment traiter une infection à leptospirose ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement comprend des antibiotiques et un suivi médical pour éviter les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements pour la maladie de Lyme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antibiotiques sont le traitement principal, surtout s'ils sont administrés tôt."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la dengue ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la dengue sévère, pouvant entraîner des hémorragies et un choc."
}
},
{
"@type": "Question",
"name": "Quels risques associés au chikungunya ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs articulaires chroniques peuvent persister longtemps après l'infection."
}
},
{
"@type": "Question",
"name": "Quelles complications de l'infection par le virus Zika ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le virus peut causer des malformations congénitales si contracté pendant la grossesse."
}
},
{
"@type": "Question",
"name": "Quelles complications de la leptospirose ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions rénales, hépatiques et des hémorragies pulmonaires."
}
},
{
"@type": "Question",
"name": "Quels risques de la maladie de Lyme non traitée ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des problèmes neurologiques et des douleurs articulaires chroniques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour la dengue ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent vivre dans des zones tropicales et avoir des antécédents d'infection."
}
},
{
"@type": "Question",
"name": "Qui est à risque pour le chikungunya ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées et celles avec des maladies chroniques sont plus vulnérables."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de virus Zika ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Voyager dans des zones endommagées par le virus et être enceinte augmentent le risque."
}
},
{
"@type": "Question",
"name": "Quels sont les risques associés à la leptospirose ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes travaillant en milieu rural ou en contact avec des eaux contaminées sont à risque."
}
},
{
"@type": "Question",
"name": "Qui est à risque pour la maladie de Lyme ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes vivant dans des zones boisées ou ayant des activités de plein air sont à risque."
}
}
]
}
]
}
Historically, the detection of prostate cancer relied upon a systematic yet random sampling of the prostate by transrectal ultrasound guided biopsy. This approach was a nontargeted technique that led ...
Mucinous adenocarcinoma of the urethra is extremely rare, even more so in a setting of postradiation therapy, with only 3 cases reported up to date including the first case published by our group in 2...
It is a known fact that the role of microRNAs (miRNA) has a very important place in cancer development and progression. miRNAs target a significant part of pathways as well as genes. This study aimed ...
Peripheral blood mononuclear cells (PBMCs) and tissue samples were collected from prostate cancer (PCa) (n: 20) and benign prostatic hyperplasia (BPH) (n: 20) patients. Total RNA isolation was perform...
In tissue samples, 37 different expressed miRNAs were identified in PCa patients compared to BPH patients. In PBMCs samples, 27 different expressed miRNAs were identified in PCa patients compared to b...
Our results suggested that determined common hsa-miR-494-3p, hsa-miR-3128, hsa-miR-8084 and their target HIF1A, AVRP1A, NHS, INSL4 may play a crucial role in therapeutic and early diagnostic strategie...
Although it is thought that prostatitis or benign prostatic hyperplasia (BPH) is related to prostate cancer (PCa), the underlying causal effects of these diseases are unclear....
We assessed the causal relationship between prostatitis or BPH and PCa using a two-sample Mendelian randomization (MR) approach. The data utilized in this study were sourced from genome-wide associati...
MR analysis showed that BPH had a significant causal effect on PCa (Odds Ratio = 1.209, 95% Confidence Interval: 0.098-0.281, P = 5.079 × 10...
This MR study supports that BPH has a positive causal effect on PCa, while genetically predicted prostatitis has no causal effect on PCa. Nonetheless, further studies should explore the underlying bio...
In recent decades, there has been an increasing role for magnetic resonance imaging (MRI) in the detection of clinically significant prostate cancer (csPC). The purpose of this review is to provide an...
In diagnosing clinically significant prostate cancer pre-biopsy, advances include our understanding of MRI-targeted biopsy, the role of biparametric MRI (non-contrast) and changing indications, for ex...
The utility of MRI in detecting csPC has been demonstrated in many clinical scenarios, initially from simply diagnosing csPC pre-biopsy, now to screening, active surveillance, clinical staging, and de...
For metastatic hormone naïve prostate cancer patients, androgen deprivation therapy (ADT) with escalation therapy including docetaxel and/or androgen targeting drugs is the standard therapy. However, ...
Prostate biopsies from 92 patients with metastatic hormone naïve PC (PSA > 80 ng/mL or clinical metastases) were immunohistochemically evaluated for PSA and Ki67. Gene expression analysis was performe...
The immunohistochemical score for PSA was the strongest prognostic factor for progression-free and overall survival after ADT. Consequently, the ratio between Ki67 and PSA displayed a stronger prognos...
PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The re...
Combined magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) may enhance diagnosis, aid surgical planning and intra-operative orientation for prostate biopsy...
To investigate the value of serum free prostate-specific antigen density (fPSAD) in the diagnosis of prostate cancer (PCa)....
The data of 558 patients who underwent transrectal ultrasound-guided prostate biopsy were retrospectively analyzed. According to the pathological results, the patients were divided into a PCa group an...
tPSA, PSAD, (f/t)/PSAD, and fPSAD had high accuracy in predicting PCa with AUC values of 0.820, 0.900, 0.846, and 0.867. fPSAD showed lower diagnostic sensitivity but significantly higher specificity ...
With the optimal cutoff value of 0.062, fPSAD has a higher diagnostic value for PCa than tPSA, f/tPSA, (f/t)/PSAD, and PSAD, and can well predict the risk of PCa, significantly improve the clinical di...
The challenges in pathology and in structuring of data are increasing. Although considerable amounts of data are generated during the pathological diagnostic process, these data are often not availabl...
The aim of the work was the development of a digital system for the direct and high-quality acquisition of structured pathology data using the example of biopsy-based diagnostics of prostate carcinoma...
A solution was created in cooperation with the pathology laboratory information system (LIS) provider imassense GmbH (Berlin, Germany), whose LIS 'Informationssystem der digitalen Pathologie' (IS-P) i...
Over a period of about 1.5 years, a system that is capable of structured reporting according to local, national (S3 guidelines, German Cancer Society) and international (International Collaboration on...
To investigate the clinical implications of magnetic resonance imaging (MRI) negative prostate cancer (PCa) in a cohort of men undergoing transperineal prostate biopsy....
We included all men without prior diagnosis of PCa undergoing transperineal template saturation ± fusion-guided targeted biopsy of the prostate between November 2014 and March 2018. Before biopsy, all...
From 515 patients undergoing prostate biopsy, 171 (33.2%) patients had a negative and 344 (66.8%) a positive MRI. Pathology review stratified for MRI negative and positive cases revealed nsPCa in 27 (...
Only few men with MRI negative PCa need active cancer treatment at the time of diagnosis, while the majority opts for AS. Omitting prostate biopsies and performing a follow-up MRI may be a safe altern...